Direct Oral #Anticoagulants in Atrial Fibrillation Patients with Concomitant #Hyperthyroidism
Patients with hyperthyroidism were excluded from randomized clinical trials of direct oral anticoagulants(DOACs) for stroke prevention in patients with non-valvular atrial fibrillation (NVAF).. After PSSW, DOAC had a comparable risk of ischemic stroke/systemic embolism (IS/SE) and a lower risk of major bleeding (hazard ratio (HR):0.65; [95% confidential interval (CI):0.44-0.96]; P=0.0295) than warfarin among patients with hyperthyroidism. There were comparable risks of IS/SE and major bleeding … Continue reading Direct Oral #Anticoagulants in Atrial Fibrillation Patients with Concomitant #Hyperthyroidism